Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNetscientific Regulatory News (NSCI)

Share Price Information for Netscientific (NSCI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 66.50
Bid: 65.00
Ask: 68.00
Change: 0.00 (0.00%)
Spread: 3.00 (4.615%)
Open: 66.50
High: 66.50
Low: 66.50
Prev. Close: 66.50
NSCI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Wanda Awarded Two Patents

12 Dec 2017 07:00

RNS Number : 0261Z
NetScientific PLC
12 December 2017
 

NetScientific plc

("NetScientific" or the "Company" or the "Group")

 

Wanda is awarded two patents which increase its ability to detect adverse event scenarios for patients

 

London, UK - December 12th 2017 - NetScientific plc ("NetScientific", AIM:NSCI), the transatlantic healthcare IP commercialisation Group, announces the issue by the U.S. Patent and Trademark Office of two new patents exclusively licensed to its portfolio company, Wanda. The patents will significantly extend protection for the core technology used in Wanda's software application for remote health and patient management. The patents, titled, "Apparatus, System, and Method for Detecting Activities and Anomalies in Time Series Data" and "Efficient Searching of Stationary Datasets" are the result of research on clinical time-series data at UCLA.

 

Commenting on the news, NetScientific's Chief Executive Officer and Chairman of Wanda, Francois R. Martelet said: "We are delighted to announce that Wanda is further strengthening its IP, an important step in its continued corporate development. We believe Wanda's class-leading predictive and behavioural analytics platform acts as a competitive differentiator in the emerging and highly exciting Digital Health sector."

 

NetScientific holds a 61% stake on a fully diluted basis in Wanda.

 

For more information, please contact:

 

  NetScientific

François R. Martelet, M.D., CEO

Ian Postlethwaite, CFO

Tel: +44 (0)20 3514 1800

 

Consilium Strategic Communications

Mary-Jane Elliott Jessica Hodgson /

Chris Welsh / Laura Thornton

 

 

Tel: +44 (0)20 3709 5700

netscientific@consilium-comms.com

Stifel Nicolaus Europe Limited (NOMAD and Broker)

Jonathan Senior / David Arch / Ben Maddison

 Tel: +44 (0) 20 7710 7600

 

 

About NetScientific

 

NetScientific is a transatlantic healthcare technology group with an investment strategy focused on sourcing, funding and commercialising technologies that significantly improve the health and well-being of people with chronic diseases. For more information, please visit the website at www.netscientific.net

 

 

Wanda is awarded two patents which increase its ability to detect adverse event scenarios for patients

December 11th 2017

Wanda (http://yourwanda.com/), a leading digital health platform focused on advancing the effectiveness and efficiency of remote patient management and communication, has been awarded two new patents by the U.S. Patent and Trademark Office, for a total of three awarded patents in 2017. The inventions titled "Efficient Searching of Stationary Datasets" and "Apparatus, System, and Method for Detecting Activities and Anomalies in Time Series Data", are a result of research on clinical time-series data done at UCLA. Anomaly Detection is a cornerstone of effective machine learning in health care. Wanda now has the ability to identify and act upon clinical and patient behavior subtleties which are frequently overlooked and then lead to adverse events.

"We are very excited to be awarded two new patents on the analytical methodologies which drive Wanda's solutions. These inventions helps us maintain our unique advantages in the space and are strong indicators that intelligent data usage is the driving force behind our products." said Foad Dabiri, CEO of Wanda, adding "Wanda is all about applying modern software applications powered by analytics, data science and deep healthcare knowledge in a meaningful, personal way that is unique to each patient and in the way nurses, doctors and the full care team can believe and then act on the information provided."

About Wanda:

Wanda represents the next generation of digital health solutions for patient care via advancing the efficiency of medicine by using machine learning and modern software applications enabling care providers to intelligently monitor, communicate with and manage their patients leading to improved outcomes and efficiencies. More information about Wanda can be found at http://www.yourwanda.com

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAOKDDPBBDBKBD
Date   Source Headline
14th Feb 20203:12 pmRNSHolding(s) in Company
12th Feb 202011:07 amRNSPDS equity issue and related party transaction
11th Feb 20202:24 pmRNSPDS Biotechnology proposed offering
15th Jan 20207:00 amRNSBoard Change
18th Dec 201911:24 amRNSHolding(s) in Company
17th Dec 20193:04 pmRNSHolding(s) in Company
13th Dec 20191:21 pmRNSBoard Changes
21st Nov 20197:00 amRNSGlycotest receives 2nd $3m tranche of $10m finance
17th Oct 20192:14 pmRNSHolding(s) in Company
14th Oct 20197:00 amRNSAppointment to the Board
3rd Oct 20191:44 pmRNSPDS collaborates with Merck in Phase 2 studies
1st Oct 20192:10 pmRNSPDS prioritise PDS0101 in high risk HPV to Phase 2
19th Sep 20191:24 pmRNSPDS - positive data for immunotherapy treatment
19th Sep 201911:00 amRNSInterim Results for six months ended 30 June 2019
1st Aug 20191:44 pmRNSPDS second quarter 2019 financial results
31st Jul 20198:41 amRNSPDS Biotechnology Corp liquidity funding program
9th Jul 20192:58 pmRNSHolding(s) in Company
8th Jul 20194:04 pmRNSHolding(s) in Company
18th Jun 20192:27 pmRNSResult of Annual General Meeting
31st May 20197:00 amRNSPositive new data demonstrates NEATstiks potential
24th May 20199:50 amRNSNotice of AGM and Annual Report & Accounts
22nd May 20197:00 amRNSFull Year Results for the year ended 31 Dec 2018
16th May 20193:07 pmRNSPDS Biotechnology journal publication
25th Apr 20197:00 amRNSResignation of CEO
22nd Mar 20194:42 pmRNSSale of Wanda and Vortex
19th Mar 20197:00 amRNSPDS merger with Edge Therapeutics update
18th Mar 20192:09 pmRNSPDS completes merger with Edge Therapeutics
18th Mar 20192:07 pmRNSOrderly wind up of Wanda and Vortex
14th Mar 20197:00 amRNSShare Price Movement
4th Mar 201911:45 amRNSResults of General Meeting
1st Mar 201911:15 amRNSUpdate on upcoming General Meeting
27th Feb 20194:40 pmRNSSecond Price Monitoring Extn
27th Feb 20194:35 pmRNSPrice Monitoring Extension
27th Feb 20192:05 pmRNSSecond Price Monitoring Extn
27th Feb 20192:00 pmRNSPrice Monitoring Extension
25th Feb 201912:54 pmRNSHolding(s) in Company
21st Feb 20194:35 pmRNSHolding(s) in Company
20th Feb 201910:51 amRNSHolding(s) in Company
19th Feb 20192:06 pmRNSSecond Price Monitoring Extn
19th Feb 20192:00 pmRNSPrice Monitoring Extension
18th Feb 20194:54 pmRNSHolding(s) in Company
18th Feb 201911:06 amRNSSecond Price Monitoring Extn
18th Feb 201911:00 amRNSPrice Monitoring Extension
15th Feb 201912:00 pmRNSConclusion of Strategic Review
14th Feb 201912:07 pmRNSGlycotest Receives First $3m Tranche from Fosun
15th Jan 201911:08 amRNSTermination of Formal Sales Process
15th Jan 20199:37 amRNSForm 8.5 - NetScientific plc
14th Jan 201910:25 amRNSForm 8.5 - NetScientific PLC
8th Jan 201911:58 amRNSForm 8.5 - NetScientific PLC
7th Jan 201910:14 amRNSForm 8.5 - NetScientific PLC

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.